Tactile Systems Technology, Inc. (TCMD) Stock Analysis
A market-leading home-therapy med-tech with a dominant lymphedema franchise and a fast-ramping respiratory second engine—now tested by Medicare prior authorization and the race to become a digital-care platform.
Overview
Tactile Medical (TCMD) is a specialized med-tech company focused on shifting chronic-condition therapy from clinics to the home, primarily treating lymphedema and chronic pulmonary diseases (bronchiectasis/cystic fibrosis). Revenue remains anchored in lymphedema (2025: ~$278.4M; ~84% of total), powered by advanced pneumatic compression devices (Flexitouch Plus, Entre Plus, and the newly launched Nimbl), while airway clearance (AffloVest) is an increasingly important second engine (2025: ~$51.1M; +52% YoY). The products are differentiated by clinical design (Flexitouch mimics manual lymphatic drainage; AffloVest enables mobile HFCWO therapy) and are reinforced by a service-heavy model that manages complex reimbursement workflows—creating switching costs for clinicians and supporting premium economics. Operationally, TCMD recovered from early-2025 sales/CRM disruption and exited 2025 with strong Q4 acceleration (+21% revenue) and expanding profitability (76% gross margin; EBITDA +21%). Strategically, the 2026 LymphaTech acquisition and digital tools (e.g., Kylee app) aim to improve early identification and adherence, potentially expanding the addressable market. The critical near-term variable is Medicare prior authorization for PCDs beginning 4/13/26, which could create friction in patient starts and is likely to be the defining catalyst/risk for valuation re-rating.